Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT01297764 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

Study acronym: QUAD
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 10 months later Jul 2026 → Jun 2027
See other at-risk trials from Hackensack Meridian Health

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jul 2026 to Jun 2027v21
  2. 2 versions Re-verified since Feb 17, 2026, no change to tracked fieldsv19-v20
  3. Primary and study completion dates: Sep 2025 to Jul 2026v18
  4. Primary and study completion dates: Nov 2024 to Sep 2025v17
  5. Primary and study completion dates: Nov 2023 to Nov 2024
    • Secondary endpoints: details revised at 1 of 1 entry
    v16
Show 14 earlier versionsHide 14 earlier versions
  1. Primary and study completion dates: Nov 2022 to Nov 2023v15
  2. Primary and study completion dates: Aug 2022 to Nov 2022v14
  3. Primary and study completion dates: Aug 2021 to Aug 2022v13
  4. Primary and study completion dates: Aug 2020 to Aug 2021
    • Enrollment target: estimated 50 to confirmed 17
    v12
  5. Primary and study completion dates: Aug 2019 to Aug 2020v11
  6. Primary and study completion dates: Aug 2015 to Aug 2019
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v10
  7. Primary completion date: Feb 2015 to Aug 2015v9
  8. Primary completion date: Feb 2014 to Feb 2015
    • Study completion date: Feb 2015 to Aug 2015
    v8
  9. Primary completion date: Dec 2013 to Feb 2014v7
  10. Primary endpoints: 2 to 1v6 Show 5 more changesShow less
    • Study completion date: Feb 2015
    • Eligibility criteria shortened, about 34 words
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description expanded, about 174 words
    • Study arms: 0 to 1
  11. Re-verified, no change to tracked fieldsv5
  12. Primary completion date: Mar 2013 to Dec 2013v4
  13. Site contact updatedv3
  14. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the feasibility of combining four of the most active agents available for the treatment of multiple myeloma. Further the investigators will attempt to assess the activity of this combination.
Trial Details
NCT Number NCT01297764
Lead Sponsor Hackensack Meridian Health
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov